Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abivax SA Sponsored ADR ( (ABVX) ) has shared an update.
Abivax SA, a clinical-stage biotechnology company specializing in immune-regulating therapies for chronic inflammatory diseases, is advancing obefazimod (ABX464) through Phase 3 trials in moderately to severely active ulcerative colitis. The company operates between France and the United States, targeting significant unmet needs in gastrointestinal and inflammatory care.
On April 20, 2026, Abivax announced that preparatory documents for its annual ordinary and extraordinary general meeting, scheduled for May 11, 2026 in Paris, have been made available to shareholders under French legal and regulatory timelines. The materials, including the agenda and draft resolutions first noticed in the April 3, 2026 BALO publication, are accessible on the company’s website, underscoring a routine but important governance step for investors ahead of key corporate decisions.
The most recent analyst rating on (ABVX) stock is a Buy with a $170.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
The score is held down primarily by weak operating fundamentals (zero revenue in 2025, widening losses, and heavy cash burn). Technicals also lean bearish with the price below key moving averages and negative MACD. The main stabilizer is the improved balance sheet with low leverage and a larger equity base.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a clinical-stage biotechnology company based in France and the United States, focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
Average Trading Volume: 956,027
Technical Sentiment Signal: Buy
Current Market Cap: $9.7B
For detailed information about ABVX stock, go to TipRanks’ Stock Analysis page.